Clinical Trial Update: A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating IPI-504 (tanespimycin) for advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IPI-504 (tanespimycin) (tanespimycin)

Snippet

Sponsor: MedImmune LLC | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN